Survival without biliary complications after liver transplant for primary sclerosing cholangitis

Experimental and Clinical Transplantation

Volumn 11, Issue 6, 2013, Pages 510-521

  Mogl, Martina T ^a   Albert, Kathrin ^a   Pascher, Andreas ^a   Sauer, Igor ^a   Puhl, Gero ^a   Gül, Safak ^a   Schönemann, Constanze ^a   Neuhaus, Peter ^a   Guckelberger, Olaf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Hepatic failure; Human leukocyte antigen; Immunosuppression; Ulcerative colitis

Indexed keywords

HLA A ANTIGEN; HLA B8 ANTIGEN; HLA C ANTIGEN; HLA DQ2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR6 ANTIGEN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BILIARY CIRRHOSIS; BILIARY TRACT DISEASE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; END STAGE LIVER DISEASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EVENT FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION; GRAFT SURVIVAL; HUMAN; INFLAMMATORY BOWEL DISEASE; ISCHEMIA TYPE BILIARY LESION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; RECURRENT DISEASE; REOPERATION; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; ULCERATIVE COLITIS; VANISHING BILE DUCT SYNDROME;

ADOLESCENT; ADULT; AGED; BILIARY TRACT DISEASES; CHOLANGITIS, SCLEROSING; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890545150     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2013.0051     Document Type: Article

References (44)

1. Hong JC, Yersiz H, Farmer DG, et al. Longterm outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: a 10-year comparative analysis of 2,988 cases. J Am Coll Surg. 2009;208(5):682-689; discussion 689-691.
2. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12(12):1813-1824.
3. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29(4):1050-1056.
4. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology. 1983;149(1):39-44.
5. Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl. 2005;11(11):1361-1369.
6. Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmüller T, Neuhaus P. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl. 2003;9(6):612-620.
7. Ren J, Zheng BW, Wang P, et al. Revealing impaired blood supply to the bile ducts on contrast-enhanced ultrasound: a novel diagnosis method to ischemic-type biliary lesions after orthotropic liver transplantation. Ultrasound Med Biol. 2013;39(5):753-760.
8. Schmitz V, Neumann UP, Puhl G, Tran ZV, Neuhaus P, Langrehr JM. Surgical complications and long-term outcome of different biliary reconstructions in liver transplantation for primary sclerosing cholangitis-choledochoduodenostomy versus choledochojejunostomy. Am J Transplant. 2006;6(2):379-385.
9. Zimmerman MA, Baker T, Goodrich NP, et al. Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-toadult living donor liver transplantation cohort study consortium. Liver Transpl. 2013;19(3):259-267.
10. Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol. 2003;34(11):1127-1136.
11. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet. 2002;360(9349):1943-1944.
12. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14(2):138-143.
13. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6(6):1422-1429.
14. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330-340.
15. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14(2):181-185.
16. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut. 1983;24(1):38-41.
17. Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol. 2001;36(8):886-890.
18. Hov JR, Lleo A, Selmi C, et al. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol. 2010;52(5):712-717.
19. Mandelboim O, Reyburn HT, Sheu EG, et al. The binding site of NK receptors on HLA-C molecules. Immunity. 1997;6(3):341-350.
20. Radaev S, Sun PD. Structure and function of natural killer cell surface receptors. Annu Rev Biophys Biomol Struct. 2003;32:93-114.
21. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872-874.
22. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14(2):245-251.
23. Manousou P, Arvaniti V, Tsochatzis E, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010;16(1):64-73.
24. Balan V, Ruppert K, Demetris AJ, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology. 2008;48(3):878-888.
25. Neumann UP, Guckelberger O, Langrehr JM, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation. 2003;75(1):132-137.
26. Hanvesakul R, Spencer N, Cook M, et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am J Transplant. 2008;8(9):1931-1941.
27. Tran TH, Middleton D, Döhler B, et al. Reassessing the impact of donor HLA-C genotype on long-term liver transplant survival. Am J Transplant. 2009;9(7):1674-1678.
28. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl. 2010;16(11):1324-1330.
29. [No authors listed] Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658-663.
30. Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48 (suppl 1):S38-S57.
31. Lerut J, Demetris AJ, Stieber AC, et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int. 1988;1(3):127-130.
32. Guckelberger O, Stange B, Glanemann M, et al. Hepatic resection in liver transplant recipients: single center experience and review of the literature. Am J Transplant. 2005;5(10):2403-2409.
33. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2003;9(7):727-732.
34. Bjøro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis. 2006;26(1):69-79.
35. Cullen S, Chapman R. Aetiopathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2000;15(4):577-589.
36. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 2002;359(9301):150-157.
37. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6(3):244-251.
38. Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999;53(5):459-469.
39. Wiencke K, Karlsen TH, Boberg KM, et al. Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens. 2007;69(2):161-169.
40. Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, Klintmalm G, Bryan C, Van Thiel D, Starzl TE. Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation. 1988;46(3):372-377.
41. Doran TJ, Geczy AF, Painter D, McCaughan G, Sheil AG, Süsal C, Opelz G. A large, single center investigation of the immunogenetic factors affecting liver transplantation. Transplantation. 2000; 69(7):1491-1498.
42. Opelz G. Preliminary analysis of HLA matching in pancreas and liver transplantation. Collaborative Transplant Study. Transplant Proc. 1993;25(4):2652-2653.
43. Kashyap R, Mantry P, Sharma R, et al. Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis. J Gastrointest Surg. 2009;13(8):1480-1486.
44. Egawa H, Taira K, Teramukai S, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig Dis Sci. 2009;54(6):1347-1354.